Developer docs
API playgroundTry for free, no card

Search company profiles

CTIBiotech

Full company profile

uuid0002csz

Namestring
CTIBiotech
Legal namestring
CTIBIOTECH USA Inc.
Websiteurl
ctibiotech.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

CTIBiotech is a French-headquartered Contract Research, Development, and Manufacturing Organization (CRDMO) that builds predictive 3D bioprinted human tissue and cell bioassays to replace animal testing in preclinical research. Founded in 2009 in Lyon by Professor Colin McGuckin and Dr. Nico Forraz, the company operates an 800m² ISO 9001:2015-certified laboratory in Meyzieu (Lyon), an authorized human-tissue biobank of over 40,000 (referenced up to 50,000) clinical samples, and a recently launched North American subsidiary (CTIBIOTECH USA) at BioLabs for Advanced Therapeutics in Philadelphia. Its commercial offering is organized into three industry-aligned lines: CTI Skin (3D bioprinted skin models, sebaceous and sweat gland systems, the world's first computer-connected bioprinted skin with sensory nervous system, plus CTIBabySkin® and SEBOKIT), CTI Pharma (CTIONCOTEST™ microtumor platform, ONCOKIT Breast, CTILiverbox, and OrgaEar inner ear organoids for cancer, liver, and hearing-disorder drug screening), and CTI Biosourcing (sale of ethically sourced human cells, tissues, and biospecimens via the Independent Biobank catalog).

The company monetizes across five revenue streams: CRDMO fee-for-service contracts (drug screening, toxicology, bioassay co-creation, GLP toxicology and bioanalytical services), direct sale of turnkey research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®), transactional supply of biospecimens from the biobank, custom 3D tissue model co-development projects, and licensing of proprietary New Approach Methodologies (NAMs) and intellectual property — including $15M of IP assets committed to the U.S. market at launch. Pricing is quote-based and project-specific across all streams. Customer segments span pharmaceutical and biotech R&D, cosmetic and dermatocosmetics, medical device and chemical developers, and academic and hospital research laboratories, served through direct enterprise sales in Lyon and Philadelphia, a global authorized distributor network across more than 30 countries, and online research marketplaces (Scientist.com, Biolabs marketplace, Labscoop). The company maintains 11-50 employees and partners with Bpifrance/France 2030, BioDuro, Sanofi, University of Lyon, SATT AxLR, CILCARE, Centre Léon Bérard, Hospices Civils de Lyon, and Transgene, with Edmond de Rothschild holding an exclusive investor relations mandate.

Short descriptiontext

CTIBiotech is a French-headquartered CRDMO that builds 3D bioprinted human tissue and cell bioassays as predictive, ethical alternatives to animal testing for pharmaceutical, biotech, cosmetic, and academic clients across more than 30 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMeyzieu, France
HQ citystring
Meyzieu
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting, human tissue models, preclinical contract research, stem cell bioassays, animal testing alternatives
Industry2 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
  • Blood and Organ Banks621991
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassays
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model5 records
1Contract Research, Development, and Manufacturing Organization (CRDMO) services
TypeProfessional Services
Description

Fee-for-service contract research, drug screening, toxicology testing, bioassay co-creation, GLP toxicology and bioanalytical services for pharmaceutical, biotech, hospitals, and universities, with bi-laboratory capabilities in Lyon and Philadelphia.

ctibiotech.com
2Sale of turnkey research kits and products
TypeHardware Sales
Description

Direct sale of ready-to-use kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®) and turnkey biological kits to research and testing laboratories.

ctibiotech.com
3Sale of human cells, tissues, and biosourced biospecimens
TypeTransaction Fee
Description

Direct supply of human cells and tissues (blood, serum, single cell types, complex tissue requests) from the authorized biobank to researchers worldwide; samples provided for R&D but not for transplant.

ctibiotech.com
4Custom 3D human tissue model development / co-development projects
TypeProfessional Services
Description

Custom bioassay co-creation and tailored 3D tissue model development in collaboration with partners (e.g., cancer, immunology, and disease-specific pathologies); CTIONCOTEST dual-revenue strategy of kit sales plus CRDMO services.

ctibiotech.com
5Licensing of proprietary 3D bioprinted bioassays and intellectual property
TypeLicensing Royalties
Description

Provision of proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets; $15 million of intellectual property assets were brought into the U.S. market at launch.

ctibiotech.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Quote-based, project-specific pricing
ModelOther
Notes

Pricing not publicly disclosed; customers must contact regional teams (Europe/Asia or USA/Canada) to request quotes for services, products, and collaborations.

ctibiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1CTI Skin
Description

Skin tissues innovation and testing; advanced predictive human cell bioassays for skin, including full ex vivo human skin, sebaceous or sweat glands, and skin immune cells. World's most advanced 3D bioprinted skin models.

ctibiotech.com
+8 more records
Core offering1 text field

CTIBiotech is a Contract Research, Development, and Manufacturing Organization (CRDMO) that produces 3D bioprinted human tissues, organoids, and cell-based bioassays from stem cells and ethically sourced surgical tissues. It sells ready-to-use research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin), supplies human biospecimens from its authorized biobank, and provides contract drug screening, toxicology, and custom tissue model development services to pharmaceutical, biotech, cosmetic, chemical, medical device, hospital, and academic clients across more than 30 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 95% of new cancer drugs currently fail in human clinical trials — CTIBIOTECH aims to address this with predictive 3D bioprinted human-derived assays.
+4 more records
Product overview1 text field

CTIBiotech operates as a French Contract Research, Development, and Manufacturing Organization (CRDMO) built around three core industry-aligned product lines—CTI Skin (preclinical skin bioassays and 3D bioprinted skin models for cosmetics, dermatology, and devices), CTI Pharma / CTIPharma™ (cancer and disease research bioassays including CTIONCOTEST™ microtumor platforms, ONCOKIT Breast, and CTILiverbox organoid services), and CTI Biosourcing (an ISO-aligned biobank of more than 50,000 ethically sourced human samples distributed via the Independent Biobank live inventory). These three pillars are complemented by a portfolio of named product kits and models—CTIBabySkin®, SEBOKIT, ONCOKIT Breast, CTILiverbox, the CTIONCOTEST™ microtumor platform, the OrgaEar inner-ear organoid project, and a computer-connected bioprinted skin with sensory nervous system—together with a CRDMO contract-research service for assay development, drug screening, and toxicity testing. As of May 2026 this portfolio is delivered through CTIBIOTECH USA™, a Philadelphia-based North American subsidiary operating from BioLabs for Advanced Therapeutics.

Product and service9 records
1CTI Skin (CTISKIN)
CategoryPreclinical skin bioassays
Description

3D bioprinted full ex vivo human skin models, including sebaceous and sweat glands and skin immune cells, used for pharmaceutical, cosmetic, chemical, and medical-device testing. Includes the world's first computer-connected lab-grown bioprinted skin with a sensory nervous system for instantaneous cosmetics and fragrance testing.

2CTI Pharma (CTIPharma)
CategoryPharmaceutical preclinical testing services
Description

Cancer and human disease research bioassays and 3D tissue models for pharmaceutical, biotech, hospital, and university clients, including bioassay co-creation, drug and device testing, plastics and vaccine testing, and oncology screening systems.

3CTI Biosourcing
CategoryHuman biospecimen supply / biobank
Description

Full-authorized human tissue and cell biobank with capacity of over 40,000 (referenced as over 50,000) clinical samples, connected to an international hospital network. Supplies single cell types, blood, serum, complex tissues, ready-to-use kits, processed cells, and culture media for R&D use (not for transplant).

4ONCOKIT Breast
CategoryOncology research kit
Description

Patient-derived 3D tumor organoid kit that reproduces key breast tumor features including proliferation, viability, and biomarker expression, enabling reliable preclinical assessment of response to chemotherapies, targeted therapies, and immunotherapies.

5CTILiverbox
CategoryLiver toxicology / hepatotoxicity testing
Description

In vitro liver preclinical platform using cell-line based 3D liver organoids that enable assessment of drug metabolism and hepatotoxicity in physiologically relevant human models, providing reproducible and predictive data for pharmaceutical and biotech partners.

6SEBOKIT
CategorySebocyte / dermatology research kit
Description

Standardized ready-to-use primary human sebocyte kit enabling laboratories to perform functional assays without primary cell isolation and culture challenges; supports dermatology and cosmetic research on sebum production, skin homeostasis, microbiota balance, acne, inflammation, and lipid metabolism.

7CTIBabySkin
CategoryEthical skin model for sensitive/baby skin testing
Description

Ethical skin model developed from umbilical cord tissues, designed for cosmetic, dermatological, and pharmaceutical industries. Mimics the biological characteristics of young, delicate, and sensitive skin, enabling product testing in a human-physiology-respecting environment without animal experimentation.

8CTIONCOTEST
CategoryPersonalized cancer microtumor platform
Description

3D bioprinted microtumor platform that produces standardized human microtumors directly from a specific cancer patient's primary tumor cells via an automated, industrial-scale process. Targets breast, colon, and pancreatic cancers; mimics the tumor microenvironment (including hypoxic and necrotic zones) with record-breaking cellular viability of 128 days.

9CTIBIOTECH USA CRDMO Services
CategoryCRDMO services (North American operations)
Description

North American CRDMO operations launched in May 2026 from BioLabs for Advanced Therapeutics in Philadelphia's "Cellicon Valley" hub; delivers proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership41 partners
1SelectUSA (U.S. Department of Commerce)
Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2026-05-04
Description

U.S. Federal Government program that hosted the official launch of CTIBIOTECH USA at the SelectUSA Investment Summit in Washington, D.C. on May 4, 2026; provided instrumental support for the U.S. expansion.

businesswire.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-04
Description

Senior Managing Director David Briel participated in the CTIBIOTECH USA launch at SelectUSA; supported the company's Pennsylvania expansion.

3Chamber of Commerce of Lyon Métropole
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-04
Description

French regional chamber providing ongoing support to CTIBIOTECH's international expansion and the CTIBIOTECH USA launch.

ctibiotech.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-04
Description

Regional government providing ongoing backing for CTIBIOTECH's international development.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

CTIBIOTECH has partnered with Biolabs for its first laboratory and offices in the USA, hosting CTIBIOTECH USA in the Curtis neighborhood of Philadelphia's 'Cellicon Valley' life sciences hub.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Strategic partnership to create an integrated preclinical development platform combining drug discovery through IND submission services. Merges BioDuro's discovery chemistry, biology, DMPK, pharmacology, and manufacturing with CTI Biotechnology's GLP toxicology and bioanalytical services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Leading French cancer center; key academic/clinical collaborator on the CTIONCOTEST project for 3D bioprinted cancer models.

8Hospices Civils de Lyon (HCL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Major French academic hospital group; key clinical collaborator on the CTIONCOTEST project.

ctibiotech.com
9Transgene
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

French biopharmaceutical company specializing in immunotherapy; industrial collaborator on the CTIONCOTEST project.

ctibiotech.com
10GenXMap
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Industrial partner in the CTIONCOTEST project ecosystem for personalized cancer care.

ctibiotech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Industrial partner in the CTIONCOTEST project ecosystem; supports preclinical oncology services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-09
Description

SATT AxLR (Occitanie Méditerranée technology transfer office) selected CTIBIOTECH to develop the OrgaEar project, a strategic collaboration to create world-first 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-09
Description

CILCARE (hearing health biotech) partnered with CTIBIOTECH on the OrgaEar project to develop 3D bioprinted inner ear organoids from hiPSC for advanced pharmacological screening in hearing disorders.

14Metron Technology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Strategic cooperation agreement signed at the 2024 OBV International Cosmetics Conference in Shanghai for the launch of CTISkin technologies in China.

ctibiotech.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of Europe's largest pharmaceutical companies developing advanced medicine solutions; listed as a strategic partner on CTIBIOTECH's partnerships page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

129,000 students and 11,000 educators/researchers; one of the leading universities in Europe and a CTIBIOTECH strategic partner.

17LyonBiopole
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Accelerates innovation in health in the Lyon region; CTIONCOTEST project is labelled by the Lyon biopôle Auvergne-Rhône-Alpes competitiveness cluster and integrates this world-class network.

ctibiotech.com
Strategic tierMinorTypeOthers
Description

High performance temperature-controlled packaging systems and expert in reuse & reverse logistics; supports CTIBIOTECH's biospecimen distribution.

Strategic tierFlagshipTypeGTM or Marketing Partner
Description

National agency supporting the international development of the French economy; ongoing partner backing CTIBIOTECH's U.S. and global expansion including the SelectUSA launch.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Regional agency supporting companies to develop and grow with government support; key partner in CTIBIOTECH's international expansion.

21Business Pennsylvania
Strategic tierCoreTypeGTM or Marketing Partner
Description

State agency supporting companies to grow and develop in Pennsylvania; partner in CTIBIOTECH USA's Philadelphia expansion.

ctibiotech.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Brings area businesses and civic leaders together to promote growth; acknowledged as supporting CTIBIOTECH USA's launch.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Government administration of Philadelphia; welcomed CTIBIOTECH USA into the local biotechnology ecosystem at the SelectUSA launch.

24Cosmetic Valley
Strategic tierMinorTypeGTM or Marketing Partner
Description

Promotes national cooperation in the French cosmetics industries; CTIBIOTECH strategic partner.

ctibiotech.com
25Cosmet'InLyon (CED European Center of Dermocosmetology)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cooperation between cosmetics and testing companies in Central France; CTIBIOTECH partner.

ctibiotech.com
26Société Française de Cosmétologie (SFC) / IFSCC
Strategic tierCoreTypeGTM or Marketing Partner
Description

French Society of Cosmetology and the International Federation of Cosmetic Chemists; scientific partners recognizing CTIBIOTECH via Top 10 Poster (IFSCC 2025) and Young Researcher Award.

ctibiotech.com
27University of Plovdiv (Medical University Plovdiv)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bilingual Bulgarian-English medical school university cooperating with CTIBIOTECH in cancer research; key collaborator on the CTIONCOTEST project.

ctibiotech.com
28Franco-Chinese Institute Lyon
Strategic tierMinorTypeGTM or Marketing Partner
Description

Creates cultural, economic and academic bridges between China and France; CTIBIOTECH strategic partner.

ctibiotech.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Helps companies develop in the Lyon region and internationally together with the metropole mayors and government.

30French Army / École Polytechnique / Institut Pasteur
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CTIBIOTECH has worked on a significant innovation project with the French Army, LPP, and the Institut Pasteur in Paris.

ctibiotech.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Industrial cooperation between Europe and Japan; CTIBIOTECH partner.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Cooperation and networking partner.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Local government and municipal business support in Meyzieu, where CTIBIOTECH's main French facility is located.

34DNA Avocats
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Legal representatives of CTIBIOTECH; David Nataf specializes in French corporate law with focus on science and biotechnologies; Vincent Muller handles litigation and defence; Tim Hughes specializes in UK law and international business.

ctibiotech.com
35Advolis Orfis (Baker Tilly)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Finance representative of CTIBIOTECH; one of the largest finance, accounting, and human resources groups in France; lead contact Valerie Malnoy.

ctibiotech.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Accelerates innovation and performance of companies and territories for responsible development and sustainable growth; advisor for tax, finance, and growth.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Cosmetics / skin advisor Philippe Msika, experienced professional from the cosmetics, beauty, and personal care sector.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Provides training and personalized support for certification implementation; regulatory advisor.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Design and marketing company advising on all aspects of communications in French and English.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Major European life-science distributor and webinar co-host with CTIBIOTECH (e.g., CTISKIN Ethical Skin Testing Solution webinar April 3, 2025).

41Oriental Beauty Valley (OBV)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

China cosmetics industry cluster in Fengxian, Shanghai. CTIBIOTECH CEO Dr. Nico Forraz announced launch of CTISkin technologies in China via partnership with Metron Technology and OBV at the 2024 OBV International Cosmetics Conference.

ctibiotech.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in 3D bioprinting of human tissues for preclinical research and therapeutic applications. Closely comparable to CTIBIOTECH's core bioprinting platform and oncology/tissue-modeling thesis, though focused on different tissue franchises.

TypeDirect peer
Description

Global leader in bioprinting technologies, bioinks, and lab automation for life sciences. Competes with CTIBIOTECH across 3D bioprinting hardware, consumables, and tissue engineering services.

TypeDirect peer
Description

Developer of validated 3D reconstructed human tissue models (EpiDerm, EpiOcular, Melanoma) used for cosmetics, pharmaceutical, and chemical safety testing — a direct competitor to CTIBIOTECH's CTI Skin and CTIBabySkin portfolio.

TypeDirect peer
Description

Provider of organ-on-chip platforms (Liver-Chip, Intestine-Chip) for preclinical drug discovery. Comparable to CTIBIOTECH as an alternative-to-animal-testing platform serving pharma R&D, though differentiated by microfluidic chip architecture.

TypeDirect peer
Description

Swiss 3D in vitro microtissue and organoid specialist serving pharma toxicology and disease modeling. Overlaps directly with CTIBIOTECH's 3D microtumor (CTIONCOTEST) and liver (CTILiverbox) offerings.

TypeDirect peer
Description

Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models in drug screening. Competes with CTIBIOTECH for pharma R&D budget allocated to human-relevant preclinical assays.

7SkinEthic (L'Oréal)
TypeDirect peer
Description

L'Oréal-owned pioneer of reconstructed human epidermis (Episkin, SkinEthic) for cosmetic and chemical safety testing. Direct competitor to CTIBIOTECH's CTISKIN line, with the strategic backing of a global cosmetics conglomerate.

TypeEmerging player
Description

Stem-cell and iPSC-derived products and services for drug discovery, including organoids and disease models. Comparable to CTIBIOTECH's iPSC-derived OrgaEar and CTI Biosourcing capabilities, with overlap on Axol Biosciences (also a CTIBIOTECH partner).

TypeBroad incumbent
Description

Global CRO/CDMO incumbent offering end-to-end preclinical research services. Represents the scaled incumbent alternative against which CTIBIOTECH competes for pharma R&D outsourcing dollars, especially after the BioDuro partnership.

TypeBroad incumbent
Description

World-leading CDMO with a cell-and-gene-therapies and biological-products footprint. Represents the broader incumbent benchmark for what CTIBIOTECH's CRDMO offering could scale into, including biological manufacturing and biospecimen supply chains.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CTIBiotech

Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassaysctibiotech.com

CTIBiotech is a French-headquartered CRDMO that builds 3D bioprinted human tissue and cell bioassays as predictive, ethical alternatives to animal testing for pharmaceutical, biotech, cosmetic, and academic clients across more than 30 countries.

What CTIBiotech does

CTIBiotech is a French-headquartered Contract Research, Development, and Manufacturing Organization (CRDMO) that builds predictive 3D bioprinted human tissue and cell bioassays to replace animal testing in preclinical research. Founded in 2009 in Lyon by Professor Colin McGuckin and Dr. Nico Forraz, the company operates an 800m² ISO 9001:2015-certified laboratory in Meyzieu (Lyon), an authorized human-tissue biobank of over 40,000 (referenced up to 50,000) clinical samples, and a recently launched North American subsidiary (CTIBIOTECH USA) at BioLabs for Advanced Therapeutics in Philadelphia. Its commercial offering is organized into three industry-aligned lines: CTI Skin (3D bioprinted skin models, sebaceous and sweat gland systems, the world's first computer-connected bioprinted skin with sensory nervous system, plus CTIBabySkin® and SEBOKIT), CTI Pharma (CTIONCOTEST™ microtumor platform, ONCOKIT Breast, CTILiverbox, and OrgaEar inner ear organoids for cancer, liver, and hearing-disorder drug screening), and CTI Biosourcing (sale of ethically sourced human cells, tissues, and biospecimens via the Independent Biobank catalog).

The company monetizes across five revenue streams: CRDMO fee-for-service contracts (drug screening, toxicology, bioassay co-creation, GLP toxicology and bioanalytical services), direct sale of turnkey research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®), transactional supply of biospecimens from the biobank, custom 3D tissue model co-development projects, and licensing of proprietary New Approach Methodologies (NAMs) and intellectual property — including $15M of IP assets committed to the U.S. market at launch. Pricing is quote-based and project-specific across all streams. Customer segments span pharmaceutical and biotech R&D, cosmetic and dermatocosmetics, medical device and chemical developers, and academic and hospital research laboratories, served through direct enterprise sales in Lyon and Philadelphia, a global authorized distributor network across more than 30 countries, and online research marketplaces (Scientist.com, Biolabs marketplace, Labscoop). The company maintains 11-50 employees and partners with Bpifrance/France 2030, BioDuro, Sanofi, University of Lyon, SATT AxLR, CILCARE, Centre Léon Bérard, Hospices Civils de Lyon, and Transgene, with Edmond de Rothschild holding an exclusive investor relations mandate.

CTIBiotech firmographics

Firmographics
Name
CTIBiotech
Legal name
CTIBIOTECH USA Inc.
Website
https://ctibiotech.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
CTIBiotech is a French-headquartered CRDMO that builds 3D bioprinted human tissue and cell bioassays as predictive, ethical alternatives to animal testing for pharmaceutical, biotech, cosmetic, and academic clients across more than 30 countries.
Ownership category
akta.pro rank

CTIBiotech industry classification

Industry
Product category
Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassays
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • 3D bioprinting
  • Human tissue models
  • Preclinical contract research
  • Stem cell bioassays
  • Animal testing alternatives

Where CTIBiotech is headquartered

Location

Headquarters

HQ city
Meyzieu
HQ country
France
HQ region
Europe

Offices2 records

Markets served

CTIBiotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research, Development, and Manufacturing Organization (CRDMO) services: Fee-for-service contract research, drug screening, toxicology testing, bioassay co-creation, GLP toxicology and bioanalytical services for pharmaceutical, biotech, hospitals, and universities, with bi-laboratory capabilities in Lyon and Philadelphia.
  2. Sale of turnkey research kits and products: Direct sale of ready-to-use kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin®) and turnkey biological kits to research and testing laboratories.
  3. Sale of human cells, tissues, and biosourced biospecimens: Direct supply of human cells and tissues (blood, serum, single cell types, complex tissue requests) from the authorized biobank to researchers worldwide; samples provided for R&D but not for transplant.
  4. Custom 3D human tissue model development / co-development projects: Custom bioassay co-creation and tailored 3D tissue model development in collaboration with partners (e.g., cancer, immunology, and disease-specific pathologies); CTIONCOTEST dual-revenue strategy of kit sales plus CRDMO services.
  5. Licensing of proprietary 3D bioprinted bioassays and intellectual property: Provision of proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets; $15 million of intellectual property assets were brought into the U.S. market at launch.

Pricing tiers

ModelBillingPrice
Other—Quote-based, project-specific pricing

Go-to-market motion5 records

Distribution channels5 records

Marketing channels9 records

CTIBiotech product offering

Product offering

Core offering

CTIBiotech is a Contract Research, Development, and Manufacturing Organization (CRDMO) that produces 3D bioprinted human tissues, organoids, and cell-based bioassays from stem cells and ethically sourced surgical tissues. It sells ready-to-use research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin), supplies human biospecimens from its authorized biobank, and provides contract drug screening, toxicology, and custom tissue model development services to pharmaceutical, biotech, cosmetic, chemical, medical device, hospital, and academic clients across more than 30 countries.

Product overview

CTIBiotech operates as a French Contract Research, Development, and Manufacturing Organization (CRDMO) built around three core industry-aligned product lines—CTI Skin (preclinical skin bioassays and 3D bioprinted skin models for cosmetics, dermatology, and devices), CTI Pharma / CTIPharma™ (cancer and disease research bioassays including CTIONCOTEST™ microtumor platforms, ONCOKIT Breast, and CTILiverbox organoid services), and CTI Biosourcing (an ISO-aligned biobank of more than 50,000 ethically sourced human samples distributed via the Independent Biobank live inventory). These three pillars are complemented by a portfolio of named product kits and models—CTIBabySkin®, SEBOKIT, ONCOKIT Breast, CTILiverbox, the CTIONCOTEST™ microtumor platform, the OrgaEar inner-ear organoid project, and a computer-connected bioprinted skin with sensory nervous system—together with a CRDMO contract-research service for assay development, drug screening, and toxicity testing. As of May 2026 this portfolio is delivered through CTIBIOTECH USA™, a Philadelphia-based North American subsidiary operating from BioLabs for Advanced Therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • CTI Skin: Skin tissues innovation and testing; advanced predictive human cell bioassays for skin, including full ex vivo human skin, sebaceous or sweat glands, and skin immune cells. World's most advanced 3D bioprinted skin models.
  • CTI Pharma
  • CTI Biosourcing
  • CTIBabySkin®
  • CTISKIN™
  • ONCOKIT Breast
  • CTILiverbox
  • SEBOKIT
  • CTIONCOTEST™

Products and services

  • CTI Skin (CTISKIN) 3D bioprinted full ex vivo human skin models, including sebaceous and sweat glands and skin immune cells, used for pharmaceutical, cosmetic, chemical, and medical-device testing. Includes the world's first computer-connected lab-grown bioprinted skin with a sensory nervous system for instantaneous cosmetics and fragrance testing.
  • CTI Pharma (CTIPharma) Cancer and human disease research bioassays and 3D tissue models for pharmaceutical, biotech, hospital, and university clients, including bioassay co-creation, drug and device testing, plastics and vaccine testing, and oncology screening systems.
  • CTI Biosourcing Full-authorized human tissue and cell biobank with capacity of over 40,000 (referenced as over 50,000) clinical samples, connected to an international hospital network. Supplies single cell types, blood, serum, complex tissues, ready-to-use kits, processed cells, and culture media for R&D use (not for transplant).
  • ONCOKIT Breast Patient-derived 3D tumor organoid kit that reproduces key breast tumor features including proliferation, viability, and biomarker expression, enabling reliable preclinical assessment of response to chemotherapies, targeted therapies, and immunotherapies.
  • CTILiverbox In vitro liver preclinical platform using cell-line based 3D liver organoids that enable assessment of drug metabolism and hepatotoxicity in physiologically relevant human models, providing reproducible and predictive data for pharmaceutical and biotech partners.
  • SEBOKIT Standardized ready-to-use primary human sebocyte kit enabling laboratories to perform functional assays without primary cell isolation and culture challenges; supports dermatology and cosmetic research on sebum production, skin homeostasis, microbiota balance, acne, inflammation, and lipid metabolism.
  • CTIBabySkin Ethical skin model developed from umbilical cord tissues, designed for cosmetic, dermatological, and pharmaceutical industries. Mimics the biological characteristics of young, delicate, and sensitive skin, enabling product testing in a human-physiology-respecting environment without animal experimentation.
  • CTIONCOTEST 3D bioprinted microtumor platform that produces standardized human microtumors directly from a specific cancer patient's primary tumor cells via an automated, industrial-scale process. Targets breast, colon, and pancreatic cancers; mimics the tumor microenvironment (including hypoxic and necrotic zones) with record-breaking cellular viability of 128 days.
  • CTIBIOTECH USA CRDMO Services North American CRDMO operations launched in May 2026 from BioLabs for Advanced Therapeutics in Philadelphia's "Cellicon Valley" hub; delivers proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to North American pharmaceutical, biomedical, and dermatocosmetics markets.

Quantifiable outcome

  • 95% of new cancer drugs currently fail in human clinical trials — CTIBIOTECH aims to address this with predictive 3D bioprinted human-derived assays.
  • +4 more outcomes

Companies that use CTIBiotech

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles5 records

CTIBiotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

CTIBiotech partnerships and signals

Strategic signal

Partnerships

41 partnerships are on record, tiered flagship, core and minor.

  • SelectUSA (U.S. Department of Commerce)flagshipGTM or Marketing Partner · 4 May 2026U.S. Federal Government program that hosted the official launch of CTIBIOTECH USA at the SelectUSA Investment Summit in Washington, D.C. on May 4, 2026; provided instrumental support for the U.S. expansion.
  • Pennsylvania Department of Community and Economic DevelopmentcoreGTM or Marketing Partner · 4 May 2026Senior Managing Director David Briel participated in the CTIBIOTECH USA launch at SelectUSA; supported the company's Pennsylvania expansion.
  • Chamber of Commerce of Lyon MétropolecoreGTM or Marketing Partner · 4 May 2026French regional chamber providing ongoing support to CTIBIOTECH's international expansion and the CTIBIOTECH USA launch.
  • Région Auvergne-Rhône-AlpescoreGTM or Marketing Partner · 4 May 2026Regional government providing ongoing backing for CTIBIOTECH's international development.
  • BioLabs for Advanced TherapeuticsflagshipStrategic or Co-development Partner · 1 May 2026CTIBIOTECH has partnered with Biolabs for its first laboratory and offices in the USA, hosting CTIBIOTECH USA in the Curtis neighborhood of Philadelphia's 'Cellicon Valley' life sciences hub.
  • BioDurocoreStrategic or Co-development Partner · 29 April 2026Strategic partnership to create an integrated preclinical development platform combining drug discovery through IND submission services. Merges BioDuro's discovery chemistry, biology, DMPK, pharmacology, and manufacturing with CTI Biotechnology's GLP toxicology and bioanalytical services.
  • Centre Léon BérardcoreStrategic or Co-development Partner · 28 April 2026Leading French cancer center; key academic/clinical collaborator on the CTIONCOTEST project for 3D bioprinted cancer models.
  • Hospices Civils de Lyon (HCL)coreStrategic or Co-development Partner · 28 April 2026Major French academic hospital group; key clinical collaborator on the CTIONCOTEST project.
  • TransgenecoreStrategic or Co-development Partner · 28 April 2026French biopharmaceutical company specializing in immunotherapy; industrial collaborator on the CTIONCOTEST project.
  • GenXMapminorStrategic or Co-development Partner · 28 April 2026Industrial partner in the CTIONCOTEST project ecosystem for personalized cancer care.
  • Oncodesign ServicesminorStrategic or Co-development Partner · 28 April 2026Industrial partner in the CTIONCOTEST project ecosystem; supports preclinical oncology services.
  • SATT AxLRcoreStrategic or Co-development Partner · 9 October 2025SATT AxLR (Occitanie Méditerranée technology transfer office) selected CTIBIOTECH to develop the OrgaEar project, a strategic collaboration to create world-first 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).
  • CILCAREcoreStrategic or Co-development Partner · 9 October 2025CILCARE (hearing health biotech) partnered with CTIBIOTECH on the OrgaEar project to develop 3D bioprinted inner ear organoids from hiPSC for advanced pharmacological screening in hearing disorders.
  • Metron TechnologycoreStrategic or Co-development Partner · 1 December 2023Strategic cooperation agreement signed at the 2024 OBV International Cosmetics Conference in Shanghai for the launch of CTISkin technologies in China.
  • SanoficoreStrategic or Co-development PartnerOne of Europe's largest pharmaceutical companies developing advanced medicine solutions; listed as a strategic partner on CTIBIOTECH's partnerships page.
  • University of Lyon (Université de Lyon)coreStrategic or Co-development Partner129,000 students and 11,000 educators/researchers; one of the leading universities in Europe and a CTIBIOTECH strategic partner.
  • LyonBiopolecoreStrategic or Co-development PartnerAccelerates innovation in health in the Lyon region; CTIONCOTEST project is labelled by the Lyon biopôle Auvergne-Rhône-Alpes competitiveness cluster and integrates this world-class network.
  • EMBALL'ISOminorOthersHigh performance temperature-controlled packaging systems and expert in reuse & reverse logistics; supports CTIBIOTECH's biospecimen distribution.
  • Business FranceflagshipGTM or Marketing PartnerNational agency supporting the international development of the French economy; ongoing partner backing CTIBIOTECH's U.S. and global expansion including the SelectUSA launch.
  • Auvergne Rhône-Alpes EntreprisescoreGTM or Marketing PartnerRegional agency supporting companies to develop and grow with government support; key partner in CTIBIOTECH's international expansion.
  • Business PennsylvaniacoreGTM or Marketing PartnerState agency supporting companies to grow and develop in Pennsylvania; partner in CTIBIOTECH USA's Philadelphia expansion.
  • The Chamber of Commerce for Greater PhiladelphiacoreGTM or Marketing PartnerBrings area businesses and civic leaders together to promote growth; acknowledged as supporting CTIBIOTECH USA's launch.
  • City of PhiladelphiacoreGTM or Marketing PartnerGovernment administration of Philadelphia; welcomed CTIBIOTECH USA into the local biotechnology ecosystem at the SelectUSA launch.
  • Cosmetic ValleyminorGTM or Marketing PartnerPromotes national cooperation in the French cosmetics industries; CTIBIOTECH strategic partner.
  • Cosmet'InLyon (CED European Center of Dermocosmetology)minorGTM or Marketing PartnerCooperation between cosmetics and testing companies in Central France; CTIBIOTECH partner.
  • Société Française de Cosmétologie (SFC) / IFSCCcoreGTM or Marketing PartnerFrench Society of Cosmetology and the International Federation of Cosmetic Chemists; scientific partners recognizing CTIBIOTECH via Top 10 Poster (IFSCC 2025) and Young Researcher Award.
  • University of Plovdiv (Medical University Plovdiv)coreStrategic or Co-development PartnerBilingual Bulgarian-English medical school university cooperating with CTIBIOTECH in cancer research; key collaborator on the CTIONCOTEST project.
  • Franco-Chinese Institute LyonminorGTM or Marketing PartnerCreates cultural, economic and academic bridges between China and France; CTIBIOTECH strategic partner.
  • ONLYLYON & Métropole de LyoncoreGTM or Marketing PartnerHelps companies develop in the Lyon region and internationally together with the metropole mayors and government.
  • French Army / École Polytechnique / Institut PasteurminorStrategic or Co-development PartnerCTIBIOTECH has worked on a significant innovation project with the French Army, LPP, and the Institut Pasteur in Paris.
  • EU-Japan Centre for Industrial CooperationminorGTM or Marketing PartnerIndustrial cooperation between Europe and Japan; CTIBIOTECH partner.
  • Franco-British and International Business AssociationminorGTM or Marketing PartnerCooperation and networking partner.
  • Ville de Meyzieu / AIRMminorGTM or Marketing PartnerLocal government and municipal business support in Meyzieu, where CTIBIOTECH's main French facility is located.
  • DNA AvocatscoreImplementation/ SI/ Consulting PartnerLegal representatives of CTIBIOTECH; David Nataf specializes in French corporate law with focus on science and biotechnologies; Vincent Muller handles litigation and defence; Tim Hughes specializes in UK law and international business.
  • Advolis Orfis (Baker Tilly)coreImplementation/ SI/ Consulting PartnerFinance representative of CTIBIOTECH; one of the largest finance, accounting, and human resources groups in France; lead contact Valerie Malnoy.
  • G.A.C GroupminorImplementation/ SI/ Consulting PartnerAccelerates innovation and performance of companies and territories for responsible development and sustainable growth; advisor for tax, finance, and growth.
  • MakilabminorImplementation/ SI/ Consulting PartnerCosmetics / skin advisor Philippe Msika, experienced professional from the cosmetics, beauty, and personal care sector.
  • France CertificationminorImplementation/ SI/ Consulting PartnerProvides training and personalized support for certification implementation; regulatory advisor.
  • Twinfish DesignminorGTM or Marketing PartnerDesign and marketing company advising on all aspects of communications in French and English.
  • CliniSciencesflagshipChannel Partner/ Reseller/ DistributorMajor European life-science distributor and webinar co-host with CTIBIOTECH (e.g., CTISKIN Ethical Skin Testing Solution webinar April 3, 2025).
  • Oriental Beauty Valley (OBV)coreStrategic or Co-development PartnerChina cosmetics industry cluster in Fengxian, Shanghai. CTIBIOTECH CEO Dr. Nico Forraz announced launch of CTISkin technologies in China via partnership with Metron Technology and OBV at the 2024 OBV International Cosmetics Conference.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

CTIBiotech competitors and assessment

Company assessment

Direct peers

  • Organovo: Pioneer in 3D bioprinting of human tissues for preclinical research and therapeutic applications. Closely comparable to CTIBIOTECH's core bioprinting platform and oncology/tissue-modeling thesis, though focused on different tissue franchises.
  • BICO (formerly CELLINK): Global leader in bioprinting technologies, bioinks, and lab automation for life sciences. Competes with CTIBIOTECH across 3D bioprinting hardware, consumables, and tissue engineering services.
  • MatTek Life Sciences (EpiDerm): Developer of validated 3D reconstructed human tissue models (EpiDerm, EpiOcular, Melanoma) used for cosmetics, pharmaceutical, and chemical safety testing — a direct competitor to CTIBIOTECH's CTI Skin and CTIBabySkin portfolio.
  • Emulate: Provider of organ-on-chip platforms (Liver-Chip, Intestine-Chip) for preclinical drug discovery. Comparable to CTIBIOTECH as an alternative-to-animal-testing platform serving pharma R&D, though differentiated by microfluidic chip architecture.
  • InSphero: Swiss 3D in vitro microtissue and organoid specialist serving pharma toxicology and disease modeling. Overlaps directly with CTIBIOTECH's 3D microtumor (CTIONCOTEST) and liver (CTILiverbox) offerings.
  • Mimetas: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models in drug screening. Competes with CTIBIOTECH for pharma R&D budget allocated to human-relevant preclinical assays.
  • SkinEthic (L'Oréal): L'Oréal-owned pioneer of reconstructed human epidermis (Episkin, SkinEthic) for cosmetic and chemical safety testing. Direct competitor to CTIBIOTECH's CTISKIN line, with the strategic backing of a global cosmetics conglomerate.

Emerging players

  • Reprocell (Axol Bioscience parent): Stem-cell and iPSC-derived products and services for drug discovery, including organoids and disease models. Comparable to CTIBIOTECH's iPSC-derived OrgaEar and CTI Biosourcing capabilities, with overlap on Axol Biosciences (also a CTIBIOTECH partner).

Broad incumbents

  • Charles River Laboratories: Global CRO/CDMO incumbent offering end-to-end preclinical research services. Represents the scaled incumbent alternative against which CTIBIOTECH competes for pharma R&D outsourcing dollars, especially after the BioDuro partnership.
  • Lonza: World-leading CDMO with a cell-and-gene-therapies and biological-products footprint. Represents the broader incumbent benchmark for what CTIBIOTECH's CRDMO offering could scale into, including biological manufacturing and biospecimen supply chains.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CTIBiotech social profiles

Digital presence

CTIBiotech compliance and trust

Trust signal

Compliance2 records

CTIBiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CTIBiotech leadership team

Management profile

Number of profiles

Profiles7 records

CTIBiotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CTIBiotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CTIBiotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CTIBiotech

What does CTIBiotech do?

CTIBiotech is a Contract Research, Development, and Manufacturing Organization (CRDMO) that produces 3D bioprinted human tissues, organoids, and cell-based bioassays from stem cells and ethically sourced surgical tissues. It sells ready-to-use research kits (ONCOKIT Breast, CTILiverbox, SEBOKIT, CTIBabySkin), supplies human biospecimens from its authorized biobank, and provides contract drug screening, toxicology, and custom tissue model development services to pharmaceutical, biotech, cosmetic, chemical, medical device, hospital, and academic clients across more than 30 countries.

Is CTIBiotech a public or private company?

CTIBiotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CTIBiotech founded?

CTIBiotech was founded in 2009. It employs 11 to 50 people.

Where is CTIBiotech based?

CTIBiotech is headquartered in Meyzieu, France, in the Europe region.

How does CTIBiotech make money?

Five revenue lines are on record. Contract Research, Development, and Manufacturing Organization (CRDMO) services are the primary driver. The others are sale of turnkey research kits and products, sale of human cells, tissues, and biosourced biospecimens, custom 3D human tissue model development / co-development projects and licensing of proprietary 3D bioprinted bioassays and intellectual property.

Who are CTIBiotech's main competitors?

Direct peers on record are Organovo, BICO (formerly CELLINK), MatTek Life Sciences (EpiDerm), Emulate, InSphero, Mimetas and SkinEthic (L'Oréal). Reprocell (Axol Bioscience parent) is listed as an emerging player. Broad incumbents are Charles River Laboratories and Lonza.

Does CTIBiotech have an API?

No public API is recorded for CTIBiotech.

What industry is CTIBiotech in?

CTIBiotech's product category is Contract Research, Development, and Manufacturing Organization (CRDMO) for 3D Bioprinted Human Tissue Bioassays. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deCTIBIOTECH gibt strategische Partnerschaft und Absichtserklärung mit Beijing Vital River bekannt, um die präklinische biomedizinische Innovation in China voranzutreibenCTIBIOTECH signed a strategic partnership and MOU with Beijing Vital River, a Charles River Laboratories company, in Shanghai. The alliance aims to commercialize CTIBIOTECH's human tissue bioassays and New Approach Methodologies (NAMs) in China, combining its 3D-bioprinted models with Vital River's preclinical infrastructure.Business Wire BlogCTIBIOTECH™ Announces Strategic Partnership and MOU With Beijing Vital River to Advance Preclinical Biomedical Innovation in ChinaCTIBIOTECH signed a strategic partnership and MOU with Beijing Vital River in Shanghai, aiming to commercialize its 3D bioprinted human tissue bioassays in China. The alliance combines CTIBIOTECH's NAMs with Vital River's preclinical infrastructure to accelerate drug discovery. The signing occurred during the Shanghai-Auvergne-Rhône-Alpes Economic Dialogue.FinancialContent Business PageCTIBIOTECH™ Announces Strategic Partnership and MOU With Beijing Vital River to Advance Preclinical Biomedical Innovation in ChinaCTIBIOTECH signed a strategic partnership and MOU with Beijing Vital River in Shanghai, aiming to commercialize its 3D bioprinted human tissue bioassays in China. The alliance combines CTIBIOTECH's NAMs with Vital River's preclinical infrastructure to accelerate drug discovery. The signing occurred during the Shanghai-Auvergne-Rhône-Alpes Economic Dialogue.PhiladelphiaPhiladelphia Lands French 3D Bioprinting Firm Ctibiotech As Life Sciences Sector GrowsCtibiotech, a French biotechnology firm specializing in 3D bioprinting and human tissue engineering, has established its North American headquarters at BioLabs Philadelphia, marking its entry into the U.S. market. The company aims to scale its technology for pharmaceutical and biomedical companies, offering lab-grown skin, tumor models, and stem cell-based bioassays as alternatives to animal testing in drug development and cancer research. The expansion is expected to create approximately 35 specialized biotech jobs over the next several years while strengthening Greater Philadelphia's standing in cutting-edge biomedical innovation.36krThe "Alibaba" of Beauty Raw Materials Arrives: How Does the Oriental Beauty Valley Reconstruct the Industry's Underlying Capabilities via the Cosmetics Element Service Platform?Oriental Beauty Valley launched a cosmetics raw material service platform to address supply chain inefficiencies. The platform offers information matching, compliance services, and industry-university-research cooperation, including iris and purslane projects. It aims to transform raw materials into verifiable technological assets.Via RitzauPrinting the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer CareCTIBIOTECH announced a €3 million project, CTIONCOTEST™, aimed at developing 3D bioprinted microtumors to improve preclinical cancer research and replace animal testing. The project is supported by €1.25 million in funding from France 2030 and Bpifrance, focusing on high-mortality cancers like breast, colon, and pancreatic.Business Wire BlogPrinting the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment SummitCTIBIOTECH, a French CRDMO specializing in 3D bioprinting of human tissues, has officially launched its U.S. subsidiary CTIBIOTECH USA at the SelectUSA Investment Summit in Washington, D.C., with operations based in Philadelphia's "Cellicon Valley" life sciences hub. The company announced a $27 million investment, comprising $12 million in U.S. operations over five years and $15 million in intellectual property assets, to provide its proprietary human cell and tissue bioassays directly to North American pharmaceutical and biomedical markets. The expansion aims to address the industry challenge where 95% of new cancer drugs fail during clinical trials by offering predictive human-derived biological assays that reduce reliance on animal testing.The Bakersfield CalifornianPrinting the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment SummitCTIBIOTECH announced the launch of its North American subsidiary, CTIBIOTECH USA, at the SelectUSA Investment Summit in Washington, D.C. on May 4, 2026, marking a major transatlantic expansion. The company is backing the launch with approximately $27 million in total investment, including nearly $12 million in U.S. operations over five years and $15 million in intellectual property assets, with operations based in Philadelphia's "Cellicon Valley" life sciences hub in association with BioLabs for Advanced Therapeutics. By establishing domestic manufacturing and research capabilities, the company aims to streamline procurement for North American pharmaceutical, biomedical, and dermatocosmetics researchers and accelerate the development of personalized predictive medicine using its 3D bioprinting technologies.FinSMEsCTIBIOTECH Receives €1.25M From BpifranceCTIBIOTECH, a French tissue engineering firm, received €1.25M from Bpifrance under the Aide au Développement Deeptech program. The funds will support operations and R&D for the €2.46M CTIONCOTEST project, a 3D bioprinting platform producing patient-specific microtumors for cancer research.